No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib
Dr. Jeff Sharman presents compelling data from multiple clinical trials, revealing the safety of acalabrutinib in treating blood disorders. The research, encompassing around 4,000 patient-years of acalabrutinib treatment, demonstrates no significant association with ventricular arrhythmias, a concern in similar therapies.
